Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway

American Journal of Pathology

Volumn 175, Issue 6, 2009, Pages 2557-2565

  Hamaguchi, Tsuyoshi ^a   Ono, Kenjiro ^a   Murase, Atsushi ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; FERULIC ACID; MONOMER; MYRICETIN; NORDIHYDROGUAIARETIC ACID; OLIGOMER; ROSMARINIC ACID; TROMETAMOL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 73549106551     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090417     Document Type: Article

References (75)

1. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 368:387-403
2. Younkin SG: Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol 1995, 37:287-288
3. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399:A23-31
4. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC: Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000, 6:143-150
5. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003, 6:345-351
6. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120:885-890
7. Glenner GG, Wong CW: Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA: 1985, 82:4245-4249
9. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC: Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987, 235:877-880
10. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736
11. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM: Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci USA: 1987, 84:4190-4194
12. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL: Amyloid-β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884
13. Olson MI, Shaw CM: Presenile dementia and Alzheimer's disease in mongolism. Brain 1969, 92:147-156
14. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706
15. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1992, 1:345-347
16. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, St. George-Hyslop PH: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778
17. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390
18. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999, 398:513-517
19. Ono K, Hamaguchi T, Naiki H, Yamada M: Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta 2006, 1762:575-586
20. Hamaguchi T, Ono K, Yamada M: Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 2006, 63:1538-1552
21. Walsh DM, Selkoe DJ: Aβ oligomers - a decade of discovery. J Neurochem 2007, 101:1172-1184
22. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid-β-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112
23. Klein WL, Stine WB Jr, Teplow DB: Small assemblies of unmodified amyloid-β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004, 25:569-580
24. Klein WL: Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002, 41:345-352
25. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356
26. Necula M, Kayed R, Milton S, Glabe CG: Small molecule inhibitors of aggregation indicate that amyloid-β oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007, 282: 10311-10324
27. Ono K, Hasegawa K, Naiki H, Yamada M: Preformed β-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun 2005, 330:111-116
28. Ono K, Hirohata M, Yamada M: Ferulic acid destabilizes preformed β-amyloid fibrils in vitro. Biochem Biophys Res Commun 2005, 336: 444-449
29. Ono K, Hirohata M, Yamada M: Alpha-lipoic acid exhibits anti-amyloidogenicity for β-amyloid fibrils in vitro. Biochem Biophys Res Commun 2006, 341:1046-1052
30. Hirohata M, Hasegawa K, Tsutsumi-Yasuhara S, Ohhashi Y, Ookoshi T, Ono K, Yamada M, Naiki H: The anti-amyloidogenic effect is exerted against Alzheimer's β-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry 2007, 46:1888-1899
31. Ono K, Hasegawa K, Naiki H, Yamada M: Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro. Biochim Biophys Acta 2004, 1690:193-202
32. Ono K, Hasegawa K, Yamada M, Naiki H: Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro. Biol Psychiatry 2002, 52:880-886
33. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H: Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro. J Neurochem 2002, 81:434-440
34. Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J Neurosci Res 2004, 75:742-750
35. Ono K, Hasegawa K, Naiki H, Yamada M: Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro. Neurochem Int 2006, 48:275-285
36. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M: Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003, 87:172-181
37. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, Teplow DB: Effects of grape seed-derived polyphenols on amyloid-β-protein self-assembly and cytotoxicity. J Biol Chem 2008, 283:32176-32187
38. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM: Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 2008, 28:6388-6392
39. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid-β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901
40. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007, 102:1095-1104
41. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377
42. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008, 326:196-208
43. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE: EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008, 15:558-566
44. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging 2001, 22: 993-1005
45. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits: Aβ elevation, and amyloid plaques in transgenic mice, Science 1996, 274:99-102
46. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K: Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005, 51:336-345
47. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234
48. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kolsch H, Jessen F, Schroder J, Schonknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J: Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 2008, 29: 812-818
49. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ: CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639
50. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM: Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 2007, 69:1569-1579
51. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM: Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007, 117:3393-3402
52. Glabe CG: Structural classification of toxic amyloid oligomers. J Biol Chem 2008, 283:29639-29643
53. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489
54. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG: Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007, 2:18
55. Lorenzo A, Yankner BA: β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA: 1994, 91:12243-12247
56. Petersen M, Simmonds MS: Rosmarinic acid. Phytochemistry 2003, 62:121-125
57. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T: A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Aβ(25-35). Behav Brain Res 2007, 180:139-145
58. Iuvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA: The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-β peptide-induced neurotoxicity. J Pharmacol Exp Ther 2006, 317:1143-1149
59. Luo J, Chuang T, Cheung J, Quan J, Tsai J, Sullivan C, Hector RF, Reed MJ, Meszaros K, King SR, Carlson TJ, Reaven GM: Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush (Larrea tridentata). Eur J Pharmacol 1998, 346:77-79
60. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Brignetti D, Luo J, Khandwala A, Reaven GM: Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia 1999, 42:102-106
61. Goodman Y, Steiner MR, Steiner SM, Mattson MP: Nordihydroguaiaretic acid protects hippocampal neurons against amyloid-β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 1994, 654:171-176
62. Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ: Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989, 14:175-185
63. Sreejayan, Rao MN: Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997, 49:105-107
64. Kim DS, Park SY, Kim JK: Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci Lett 2001, 303:57-61
65. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V: Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28:110-113
66. German JB, Walzem RL: The health benefits of wine. Annu Rev Nutr 2000, 20:561-593
67. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR: Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 1999, 47:2274-2279
68. Sellappan S, Akoh CC: Flavonoids and antioxidant capacity of Georgiagrown Vidalia onions. J Agric Food Chem 2002, 50:5338-5342
69. Ong KC, Khoo HE: Biological effects of myricetin. Gen Pharmacol 1997, 29:121-126
70. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H: Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 2008, 1780:819-825
71. Graf E: Antioxidant potential of ferulic acid. Free Radic Biol Med 1992, 13:435-448
72. Scott BC, Butler J, Halliwell B, Aruoma OI: Evaluation of the antioxidant actions of ferulic acid and catechins. Free Radic Res Commun 1993, 19:241-253
73. Kim HS, Cho JY, Kim DH, Yan JJ, Lee HK, Suh HW, Song DK: Inhibitory effects of long-term administration of ferulic acid on microglial activation induced by intracerebroventricular injection of β-amyloid peptide (1-42) in mice. Biol Pharm Bull 2004, 27:120-121
74. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK: Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001, 133:89-96
75. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA: Ferulic acid ethyl ester protects neurons against amyloid-β-peptide(1-42)- induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 2005, 92:749-758